Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence

Katherine E. Schlusser, Jacob Konikoff, Allison R. Kirkpatrick, Charles Morrison, Tsungai Chipato, Pai Lien Chen, Marshall Munjoma, Susan Eshleman, Oliver B. Laeyendecker

Research output: Contribution to journalArticle

Abstract

Accurate methods for cross-sectional incidence estimation are needed for HIV prevention research. The Limiting Antigen Avidity (LAg-Avidity) assay has been marketed by two vendors, Maxim Biomedical and Sedia BioSciences Corporation. Performance differences between the two versions of the assay are unknown. We tested a total 1,410 treatment-naive samples with both versions of the assay. The samples came from 176 seroconverters from the Zimbabwe Hormonal Contraception and HIV Study. The correlation between the two versions of the assay was 0.93 for the optical density (OD) and 0.86 for the normalized OD. As the difference was more pronounced for the normalized OD, the difference in assays can be attributed to the calibrators. The mean duration of recent infection (MDRI), the average time individuals infected <2 years appear recently infected, was determined for both versions using an assay cutoff of 1.5 OD-n alone or in combination with a viral load cutoff of >1,000 copies/ml. The MDRI was 137 days for Sedia and 157 days for Maxim, with a difference of 20 days (95% CI 11-30). The MDRIs decreased to 102 and 120 days with the inclusion of a viral load cutoff of >1,000 copies/ml. These results imply that use of the Sedia LAg-Avidity will result in estimates of incidence ∼13% lower than those using the Maxim LAg-Avidity.

Original languageEnglish (US)
Pages (from-to)555-557
Number of pages3
JournalAIDS Research and Human Retroviruses
Volume33
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

HIV
Antigens
Incidence
Zimbabwe
Infection
Viral Load
Contraception
Research
Therapeutics

Keywords

  • cross-sectional incidence testing
  • HIV
  • subtype C

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Short Communication : Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence. / Schlusser, Katherine E.; Konikoff, Jacob; Kirkpatrick, Allison R.; Morrison, Charles; Chipato, Tsungai; Chen, Pai Lien; Munjoma, Marshall; Eshleman, Susan; Laeyendecker, Oliver B.

In: AIDS Research and Human Retroviruses, Vol. 33, No. 6, 01.06.2017, p. 555-557.

Research output: Contribution to journalArticle

Schlusser, Katherine E. ; Konikoff, Jacob ; Kirkpatrick, Allison R. ; Morrison, Charles ; Chipato, Tsungai ; Chen, Pai Lien ; Munjoma, Marshall ; Eshleman, Susan ; Laeyendecker, Oliver B. / Short Communication : Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence. In: AIDS Research and Human Retroviruses. 2017 ; Vol. 33, No. 6. pp. 555-557.
@article{1283e6e00fe2458fb1cd17f487f1f1ba,
title = "Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence",
abstract = "Accurate methods for cross-sectional incidence estimation are needed for HIV prevention research. The Limiting Antigen Avidity (LAg-Avidity) assay has been marketed by two vendors, Maxim Biomedical and Sedia BioSciences Corporation. Performance differences between the two versions of the assay are unknown. We tested a total 1,410 treatment-naive samples with both versions of the assay. The samples came from 176 seroconverters from the Zimbabwe Hormonal Contraception and HIV Study. The correlation between the two versions of the assay was 0.93 for the optical density (OD) and 0.86 for the normalized OD. As the difference was more pronounced for the normalized OD, the difference in assays can be attributed to the calibrators. The mean duration of recent infection (MDRI), the average time individuals infected <2 years appear recently infected, was determined for both versions using an assay cutoff of 1.5 OD-n alone or in combination with a viral load cutoff of >1,000 copies/ml. The MDRI was 137 days for Sedia and 157 days for Maxim, with a difference of 20 days (95{\%} CI 11-30). The MDRIs decreased to 102 and 120 days with the inclusion of a viral load cutoff of >1,000 copies/ml. These results imply that use of the Sedia LAg-Avidity will result in estimates of incidence ∼13{\%} lower than those using the Maxim LAg-Avidity.",
keywords = "cross-sectional incidence testing, HIV, subtype C",
author = "Schlusser, {Katherine E.} and Jacob Konikoff and Kirkpatrick, {Allison R.} and Charles Morrison and Tsungai Chipato and Chen, {Pai Lien} and Marshall Munjoma and Susan Eshleman and Laeyendecker, {Oliver B.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1089/aid.2016.0245",
language = "English (US)",
volume = "33",
pages = "555--557",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Short Communication

T2 - Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence

AU - Schlusser, Katherine E.

AU - Konikoff, Jacob

AU - Kirkpatrick, Allison R.

AU - Morrison, Charles

AU - Chipato, Tsungai

AU - Chen, Pai Lien

AU - Munjoma, Marshall

AU - Eshleman, Susan

AU - Laeyendecker, Oliver B.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Accurate methods for cross-sectional incidence estimation are needed for HIV prevention research. The Limiting Antigen Avidity (LAg-Avidity) assay has been marketed by two vendors, Maxim Biomedical and Sedia BioSciences Corporation. Performance differences between the two versions of the assay are unknown. We tested a total 1,410 treatment-naive samples with both versions of the assay. The samples came from 176 seroconverters from the Zimbabwe Hormonal Contraception and HIV Study. The correlation between the two versions of the assay was 0.93 for the optical density (OD) and 0.86 for the normalized OD. As the difference was more pronounced for the normalized OD, the difference in assays can be attributed to the calibrators. The mean duration of recent infection (MDRI), the average time individuals infected <2 years appear recently infected, was determined for both versions using an assay cutoff of 1.5 OD-n alone or in combination with a viral load cutoff of >1,000 copies/ml. The MDRI was 137 days for Sedia and 157 days for Maxim, with a difference of 20 days (95% CI 11-30). The MDRIs decreased to 102 and 120 days with the inclusion of a viral load cutoff of >1,000 copies/ml. These results imply that use of the Sedia LAg-Avidity will result in estimates of incidence ∼13% lower than those using the Maxim LAg-Avidity.

AB - Accurate methods for cross-sectional incidence estimation are needed for HIV prevention research. The Limiting Antigen Avidity (LAg-Avidity) assay has been marketed by two vendors, Maxim Biomedical and Sedia BioSciences Corporation. Performance differences between the two versions of the assay are unknown. We tested a total 1,410 treatment-naive samples with both versions of the assay. The samples came from 176 seroconverters from the Zimbabwe Hormonal Contraception and HIV Study. The correlation between the two versions of the assay was 0.93 for the optical density (OD) and 0.86 for the normalized OD. As the difference was more pronounced for the normalized OD, the difference in assays can be attributed to the calibrators. The mean duration of recent infection (MDRI), the average time individuals infected <2 years appear recently infected, was determined for both versions using an assay cutoff of 1.5 OD-n alone or in combination with a viral load cutoff of >1,000 copies/ml. The MDRI was 137 days for Sedia and 157 days for Maxim, with a difference of 20 days (95% CI 11-30). The MDRIs decreased to 102 and 120 days with the inclusion of a viral load cutoff of >1,000 copies/ml. These results imply that use of the Sedia LAg-Avidity will result in estimates of incidence ∼13% lower than those using the Maxim LAg-Avidity.

KW - cross-sectional incidence testing

KW - HIV

KW - subtype C

UR - http://www.scopus.com/inward/record.url?scp=85020470672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020470672&partnerID=8YFLogxK

U2 - 10.1089/aid.2016.0245

DO - 10.1089/aid.2016.0245

M3 - Article

C2 - 28318310

AN - SCOPUS:85020470672

VL - 33

SP - 555

EP - 557

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 6

ER -